News
ISA Pharmaceuticals announces successful closing of EUR 26 million funding round
July 13, 2021
The proceeds of this round will be used to advance the lead product ISA101b towards first marketing authorization as well as to...
Read more
MIMETAS and Roche enter into a collaboration to develop human disease models for drug development
July 06, 2021
- Risk-sharing alliance on tailor-made phenotypic models for IBD and HBV
- Upfront payment and milestone payments for MIMETAS...
Read more
Sapreme will present data at the RNAi-Based Therapeutics Summit, demonstrating the potential of its Endosomal Escape Enhancing compound SPT001 to enable superior targeted delivery of oligonucleotides.
June 10, 2021
Sapreme will present data at the RNAi-Based Therapeutics Summit, demonstrating the potential of its Endosomal Escape Enhancing...
Read more
MIMETAS wins Deshima award for Dutch-Japanese business relations
June 07, 2021
MIMETAS wins Deshima award for Dutch-Japanese business relations.
Read more
Merus Presents Clinical Data on Zenocutuzumab in NRG1-fusion (NRG1+) Cancers at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting (Oral Abstract)
June 04, 2021
- 61 patients with NRG1+ cancer have been enrolled, including 45 patients evaluable for response as of the April 13, 2021 data...
Read more
Macrophage Pharma Appoints Dr Venkat Reddy as Chief Executive Officer
June 01, 2021
Macrophage Pharma Limited ('MPL') announced today that its Chief Scientific Officer (CSO), Dr Venkat Reddy PhD, has been appoin...
Read more
MIMETAS Opens Phenotypic Screening Center
May 27, 2021
Largest reported organ-on-a-chip screen ever performed on a 3D angiogenesis assay
Read more
ISA Pharmaceuticals Co-authors Publication in Nature Reviews Cancer on Therapeutic Cancer Vaccines
May 04, 2021
The Nature Reviews Cancer paper summarizes key insights gleaned from previous successful and non-successful therapeutic vaccine...
Read more
Merus Announces First Patient Treated in Phase 1/2 Clinical Trial of MCLA-129 in Advanced Lung Cancer and Other Solid Tumors
May 03, 2021
First patient has been treated in its phase 1/2 dose escalation and expansion trial evaluating MCLA-129 for the treatment of pa...
Read more
ISA has relocated to brand new Biopartner 5 building
May 03, 2021
ISA has relocated to brand new Biopartner 5 building
Read more
